These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 38697481)

  • 1. Possible impact of revisions in disc diffusion breakpoints for aminoglycosides and piperacillin/tazobactam in the 33rd edition of CLSI M100 document on clinical reporting and use in Indian settings with low susceptibility.
    Aggarwal P; Saxena S; Nagi N
    Indian J Med Microbiol; 2024; 49():100602. PubMed ID: 38697481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicenter Evaluation of the New Etest Gradient Diffusion Method for Piperacillin-Tazobactam Susceptibility Testing of
    García-Fernández S; Bala Y; Armstrong T; García-Castillo M; Burnham CA; Wallace MA; Hardy D; Zambardi G; Cantón R
    J Clin Microbiol; 2020 Jan; 58(2):. PubMed ID: 31597745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Introducing the new face of CLSI M100 in 2023: An explanatory review.
    Rai S; Dash D; Agarwal N
    Indian J Med Microbiol; 2023; 46():100432. PubMed ID: 37945125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Wide variability in Pseudomonas aeruginosa aminoglycoside results among seven susceptibility testing procedures.
    Staneck JL; Glenn S; DiPersio JR; Leist PA
    J Clin Microbiol; 1989 Oct; 27(10):2277-85. PubMed ID: 2511223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antimicrobial resistance, virulence factors, and genotypes of Pseudomonas aeruginosa clinical isolates from Gorgan, northern Iran.
    Shahri FN; Izanloo A; Goharrizi MASB; Jamali A; Bagheri H; Hjimohammadi A; Ardebili A
    Int Microbiol; 2022 Nov; 25(4):709-721. PubMed ID: 35697891
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Karlowsky JA; Lob SH; Siddiqui F; Akrich B; DeRyke CA; Young K; Motyl MR; Hawser SP; Sahm DF
    J Med Microbiol; 2023 Feb; 72(2):. PubMed ID: 36763081
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparison of Antimicrobial Susceptibility Test Results of Disk Diffusion, Gradient Strip, and Automated Dilution with Broth Microdilution for Piperacillin-Tazobactam.
    Gehring T; Kim HJ; Dibloni E; Neuenhoff M; Buechler C
    Microb Drug Resist; 2021 Oct; 27(10):1305-1311. PubMed ID: 34582726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015).
    Pfaller MA; Shortridge D; Sader HS; Castanheira M; Flamm RK
    Int J Antimicrob Agents; 2018 Feb; 51(2):181-189. PubMed ID: 28993143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicenter Evaluation of the Etest Gradient Diffusion Method for Ceftolozane-Tazobactam Susceptibility Testing of Enterobacteriaceae and Pseudomonas aeruginosa.
    Bailey AL; Armstrong T; Dwivedi HP; Denys GA; Hindler J; Campeau S; Traczewski M; Humphries R; Burnham CA
    J Clin Microbiol; 2018 Sep; 56(9):. PubMed ID: 29976590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Australia and New Zealand: Report from an Antimicrobial Surveillance Program (2013-2015).
    Pfaller MA; Shortridge D; Sader HS; Flamm RK; Castanheira M
    J Glob Antimicrob Resist; 2017 Sep; 10():186-194. PubMed ID: 28735046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of four antimicrobial susceptibility testing methods to determine the in vitro activities of piperacillin and piperacillin-tazobactam against clinical isolates of Enterobacteriaceae and Pseudomonas aeruginosa.
    Karlowsky JA; Weaver MK; Thornsberry C; Dowzicky MJ; Jones ME; Sahm DF
    J Clin Microbiol; 2003 Jul; 41(7):3339-43. PubMed ID: 12843088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of imipenem/relebactam against non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa in Latin America: SMART 2018‒2020.
    Karlowsky JA; Lob SH; Siddiqui F; Pavia J; DeRyke CA; Young K; Motyl MR; Sahm DF
    Braz J Infect Dis; 2023; 27(3):102775. PubMed ID: 37169345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimicrobial Activity of Ceftolozane-Tazobactam Tested Against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2013-2016) as Part of the Surveillance Program: Program to Assess Ceftolozane-Tazobactam Susceptibility.
    Shortridge D; Pfaller MA; Castanheira M; Flamm RK
    Microb Drug Resist; 2018 Jun; 24(5):563-577. PubMed ID: 29039729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antimicrobial Activity of Ceftazidime-Avibactam, Ceftolozane-Tazobactam and Comparators Tested Against
    Sader HS; Carvalhaes CG; Streit JM; Doyle TB; Castanheira M
    Microb Drug Resist; 2021 Mar; 27(3):342-349. PubMed ID: 32762605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Susceptibility of current clinical isolates of Pseudomonas aeruginosa and enteric gram-negative bacilli to amikacin and other aminoglycoside antibiotics.
    Dámaso D; Moreno-López M; Martínez-Beltrán J; García-Iglesias MC
    J Infect Dis; 1976 Nov; 134 SUPPL():S394-90. PubMed ID: 825591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of Ceftolozane-Tazobactam Against Gram-Negative Isolates from Australia and New Zealand as part of the PACTS Surveillance 2016-2018.
    Shortridge D; Streit J; Pfaller M; Tulloch M; Chen WT; Castanheira M
    J Glob Antimicrob Resist; 2022 Dec; 31():98-103. PubMed ID: 35988706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the Etest and disk diffusion method for detection of the activity of ceftazidime-avibactam against Enterobacterales and Pseudomonas aeruginosa in China.
    Wang Q; Zhang F; Wang Z; Chen H; Wang X; Zhang Y; Li S; Wang H
    BMC Microbiol; 2020 Jun; 20(1):187. PubMed ID: 32600252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of imipenem/relebactam against non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa in the Asia-Pacific region: SMART 2017-2020.
    Karlowsky JA; Lob SH; Chen WT; DeRyke CA; Siddiqui F; Young K; Motyl MR; Sahm DF
    Int J Antimicrob Agents; 2023 Sep; 62(3):106900. PubMed ID: 37354921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Performance of Vitek 2 for Antimicrobial Susceptibility Testing of Acinetobacter baumannii, Pseudomonas aeruginosa, and Stenotrophomonas maltophilia with Vitek 2 (2009 FDA) and CLSI M100S 26th Edition Breakpoints.
    Bobenchik AM; Deak E; Hindler JA; Charlton CL; Humphries RM
    J Clin Microbiol; 2017 Feb; 55(2):450-456. PubMed ID: 27881616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disk Correlates for Revised Clinical and Laboratory Standards Institute
    Humphries R; Tamma PD; Mathers AJ
    J Clin Microbiol; 2022 May; 60(5):e0024322. PubMed ID: 35443782
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.